HER2 Alterations in Non-Small Cell Lung Cancer : Episode 11

Video

October 17, 2022

Unmet Needs in NSCLC Therapy

Author(s):

Solange Peters, MD, PhD,Timothy Craig Allen, MD, JD, FCAP

Drs Anil Vachani and Mark Socinski continue their discussion of anti-HER2 therapies by mentioning some of the unmet needs in NSCLC treatment despite the range of available treatment options.

EP: 1.Biomarker Testing in NSCLC: Clinical Scenario

EP: 2.Approaches to Biomarker Testing in NSCLC

EP: 3.Liquid vs Solid Tumor Biopsies in NSCLC

EP: 4.HER2 Alterations in NSCLC: Clinical Scenario

EP: 5.The Role of HER2 Alterations in NSCLC

EP: 6.Testing Patients with NSCLC for HER2 Mutations

EP: 7.Current Treatment Options in NSCLC

EP: 8.Clinical Scenario: A 72-Year-Old Man with HER2-Amplified NSCLC

EP: 9.HER2-Targeted Therapies in NSCLC

EP: 10.Major Adverse Events of Anti-HER2 Therapies

Now Viewing

EP: 11.Unmet Needs in NSCLC Therapy

EP: 12.Challenges and Unmet Needs in HER2-Mutated or Amplified NSCLC

EP: 13.Novel HER2-Targeted Therapies for NSCLC

Related Content

Lung cancer, Image credit: Axel Kock – stock.adobe.com

November 20th 2024

Osimertinib Approaches EU Approval in Locally Advanced EGFR+ NSCLC After Chemoradiation

October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

November 19th 2024

Subcutaneous Pembrolizumab Plus Chemo Meets Pharmacokinetic End Points in NSCLC

October 7th 2024

Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD

November 18th 2024

Amivantamab/Lazertinib Combo Approaches EU Approval in EGFR+ Advanced NSCLC

November 16th 2024

The OncFive: Top Oncology Articles for the Week of 11/10